Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. - Wikidata - wikimedia - TriplyDB

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

http://www.wikidata.org/entity/Q37079289

about

Effects of glucose-lowering agents on ischemic stroke.Potentiation of endothelium-dependent vasorelaxation of mesenteric arteries from spontaneously hypertensive rats by gemigliptin, a dipeptidyl peptidase-4 inhibitor class of anti-diabetic drug

P2860

Q39427199-1E7F456F-0832-44B0-AAE1-AABF8FB93CB7 Q58565182-0BF5C34A-BEB7-4F40-BF62-29E1E54DA904

P2860

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

http://www.wikidata.org/entity/Q37079289

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@en

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@nl

type

label

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@en

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@nl

prefLabel

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@en

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@nl

P1433

Q37079289-4CEE1B33-5C47-4144-B7B9-247778F9E164

P1476

Q37079289-4F30621A-C76D-48E6-A65A-D87DFBF0B8F5

P2093

Q37079289-21F0C043-8D5B-4EDE-95CC-57D92FDB2770

Q37079289-6E2A5C1A-BF20-4885-BC4D-98857D6A9D61

P2860

Q37079289-0146D986-BE68-488C-B3A0-05D92A49F886

Q37079289-0EFB2CB0-DCCD-4ECD-B379-4107B5743D85

Q37079289-115E96EA-E630-46E3-B8A1-A6CD29F72CCE

Q37079289-2F0E4194-E85E-45BD-8338-200918451609

Q37079289-358B09E9-BA34-4361-8F92-A3CA1921773B

Q37079289-3E80687A-C972-4E10-A0A6-0D7198B7B0FC

Q37079289-3FA2EC17-CB0C-4346-AC23-6BE6AC92DBBD

Q37079289-412A5E2A-10A6-4C29-AD87-067BB989379C

Q37079289-4C1C6B1D-7787-44FC-B1B1-00358B429A1E

Q37079289-554E6417-D798-4AAE-BD41-731A3ECBF061

P304

Q37079289-F1A1F06D-7348-4C58-9B92-C9C974E407BE

P31

Q37079289-59A6F07B-3E32-436F-AB2B-EAE2309D2286

P433

Q37079289-123BFFC2-E101-4061-8D41-A7DF4DED0F01

P478

Q37079289-F15E65BA-EE73-4D12-B071-D90996880D8F

P577

Q37079289-D644391F-6CBC-473E-B1A6-08117B7F5753

P698

Q37079289-1090C422-062C-4BA6-85C8-9F01A21BE94D

P932

Q37079289-946F4AF7-E09D-4C34-9560-09B97F25901B

P1433

P1476

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

@en

P2093

K Tziomalos

http://www.w3.org/2001/XMLSchema#string

M Papagianni

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Standards of medical care in diabetes--2014

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

P304

195-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27418775

http://www.w3.org/2001/XMLSchema#string

P932

4938463

http://www.w3.org/2001/XMLSchema#string